IFNAR1 anticorps (pSer535, pSer539)

N° du produit ABIN361505

Détail du produit anti-IFNAR1 anticorps

Antigène: IFNAR1 (Interferon alpha/beta Receptor 1 (IFNAR1))

Épitope: pSer535, pSer539

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IFNAR1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Specificité: Specific for IFNAR1 protein phosphorylated at Ser535,539.

Réactivité croisée: Humain

Homologie: bovine, canine, mouse, non-human primate, rat, sheep

Purification: Antigen Affinity Purified from Pooled Serum

Immunogène: Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser535/539 conjugated to KLH

Information d'application

Indications d'application: Recommended Dilution: WB: 1:1000 IHC: 1:1000 Quality Control: Western blots performed on each lot.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 100 μL in 10 mM HEPES (  pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50 % glycerol.

Stock: -20 °C

Références pour anticorps anti-IFNAR1 (ABIN361505)

Bhattacharya, HuangFu, Liu, Veeranki, Baker, Koumenis, Diehl, Fuchs: "Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor." dans: The Journal of biological chemistry, Vol. 285, Issue 4, pp. 2318-25, (2010) (PubMed).

Kumar, Krolewski, Fuchs: "Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor." dans: The Journal of biological chemistry, Vol. 279, Issue 45, pp. 46614-20, (2004) (PubMed).

Détails sur IFNAR1

Antigène: IFNAR1 (Interferon alpha/beta Receptor 1 (IFNAR1))

Autre désignation: IFNAR1 (IFNAR1 Produits)

Synonymes: anticorps ifnar1, anticorps IFNAR1, anticorps CD118, anticorps Ifar, anticorps Ifnar, anticorps Ifrc, anticorps Infar, anticorps AVP, anticorps IFN-alpha-REC, anticorps IFNAR, anticorps IFNBR, anticorps IFRC, anticorps IFN-R-1, anticorps interferon alpha and beta receptor subunit 1, anticorps interferon-alpha/beta receptor alpha chain-like, anticorps interferon (alpha and beta) receptor 1, anticorps interferon alpha/beta receptor 1, anticorps IFNAR1, anticorps ifnar1, anticorps Ifnar1, anticorps LOC609830

Sujet: Interferons are widely used therapeutic agents because of their anti tumor and antiviral effects and because of their modulatory effects on the immune system (Biron, 2001, Kirkwood, 2002). These cytokines produce their effects by binding to the Type 1 Interferon-a Receptor (IFNAR1). Down regulation of this receptor plays a key role in determining the magnitude and duration of cytokine signaling. This down regulation is thought to be influenced by phosphorylation of Serine 535 and 539 in the IFNAR1 (Kumar et al., 2003). Anti-Phospho Ser535,539 IFNAR1 Western blot of immunoprecipitates from HEK 293 cells transfected with 1. Mock, 2. IFNAR1 WT, and 3. IFNAR1 S535A and S539A mutants showing specific immunolabeling of the ~110k to ~130k IFNAR1 WT. The immunolabeling is absent in IFNAR1 Ser535 and Ser539 mutants (Control). The immunolabeling is blocked by the phosphopeptide (Phos) used as the antigen but not by the corresponding dephosphopeptide (Dephos).

Poids moléculaire: 110-130 kDa

ID gène: 3654

UniProt: P17181

Pathways: Signalistation JAK/STAT, Hepatitis C